NDC 0295-1040 Salex Cream

Salicylic Acid

NDC Product Code 0295-1040

NDC Product Information

Salex Cream with NDC 0295-1040 is a a human prescription drug product labeled by Denison Pharmaceuticals, Llc. The generic name of Salex Cream is salicylic acid. The product's dosage form is cream and is administered via topical form.

Labeler Name: Denison Pharmaceuticals, Llc

Dosage Form: Cream - An emulsion, semisolid3 dosage form, usually containing > 20% water and volatiles5 and/or < 50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.

Product Type: Human Prescription Drug Additional informationCallout TooltipWhat kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.


Salex Cream Active Ingredient(s)

Additional informationCallout TooltipWhat is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • SALICYLIC ACID 60 mg/g

Inactive Ingredient(s)

Additional informationCallout TooltipAbout the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • AMMONIUM LACTATE (UNII: 67M901L9NQ)
  • BEHENTRIMONIUM METHOSULFATE (UNII: 5SHP745C61)
  • CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)
  • CETYL ALCOHOL (UNII: 936JST6JCN)
  • DIMETHICONE 350 (UNII: 2Y53S6ATLU)
  • EDETATE DISODIUM (UNII: 7FLD91C86K)
  • GLYCERIN (UNII: PDC6A3C0OX)
  • GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)
  • METHYLPARABEN (UNII: A2I8C7HI9T)
  • MINERAL OIL (UNII: T5L8T28FGP)
  • PEG-100 STEARATE (UNII: YD01N1999R)
  • PHENOXYETHANOL (UNII: HIE492ZZ3T)
  • PROPYLPARABEN (UNII: Z8IX2SC1OH)
  • WATER (UNII: 059QF0KO0R)
  • TROLAMINE (UNII: 9O3K93S3TK)

Administration Route(s)

Additional informationCallout TooltipWhat are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.

Product Labeler Information

Additional informationCallout TooltipWhat is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

* Please review the disclaimer below.

Salex Cream Product Label Images

Salex Cream Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Other

  • Rx onlyFOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE.

  • Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:
  • DRUGDESCRIPTION OF INTERACTIONSulfonylureasHypoglycemia potentiated.MethotrexateDecreases tubular reabsorption; clinical toxicity from methotrexate can result.Oral AnticoagulantsIncreased bleeding.

  • Drugs changing salicylate levels by altering renal tubular reabsorption:
  • DRUGDESCRIPTION OF INTERACTIONCorticosteroidsDecreases plasma salicylate level; tapering doses of steroids may promote salicylism.Acidifying AgentsIncreases plasma salicylate level.Alkalizing AgentsDecreased plasma salicylate levels.

  • Drugs with complicated interactions with salicylates:
  • DRUGDESCRIPTION OF INTERACTIONHeparinSalicylate decreases platelet adhesiveness and interferes with hemostasis in heparin-treated patients.PyrazinamideInhibits pyrazinamide-induced hyperuricemia.Uricosuric AgentsEffect of probenemide, sulfinpyrazone and phenylbutazone inhibited.

Manufactured for: Valeant Pharmaceuticals North America LLC


Bridgewater, NJ 08807 USA


by:Denison Pharmaceuticals, LLC


Lincoln, RI 02865 USA


PATENT NO. 6,709,663REORDER NO.


Salex


® Cream: 13548-010-17


Salex


® Lotion: 13548-011-09


Salex is a registered trademark of Valeant Pharmaceuticals International, Inc. or its affiliates. MVE is a trademark of DFB TECHNOLOGY, LTD.Any other product/brand names are trademarks of their respective owners.©Valeant Pharmaceuticals North America LLC


949770070011485

Description

Salex
® Cream contains 6% salicylic acid USP incorporated into a patented Multivesicular Emulsion (MVE) vehicle consisting of ammonium lactate, behentrimonium methosulfate, cetearyl alcohol, cetyl alcohol, dimethicone 360, disodium EDTA, glycerin, glyceryl stearate SE, methylparaben, mineral oil, PEG-100 stearate, phenoxyethanol, propylparaben, purified water and trolamine.
Salex
® Lotion contains 6% w/w salicylic acid USP incorporated into a patented Multivesicular Emulsion (MVE) vehicle consisting of ammonium lactate, behentrimonium methosulfate, cetearyl alcohol, cetyl alcohol, dimethicone 360, disodium EDTA, glycerin, glyceryl stearate SE, methylparaben, mineral oil, PEG-100 stearate, propylparaben, purified water and trolamine.
Salicylic acid is the 2-hydroxy derivative of benzoic acid having the following structure:This MVE formulation has been shown to provide gradual and prolonged release of the active ingredient into the skin.
1

Clinical Pharmacology

Salicylic acid has been shown to produce desquamation of the horny layer of skin while not effecting qualitative or quantitative changes in the structure of the viable epidermis. The mechanism of action has been attributed to a dissolution of intercellular cement substance. In a study of the percutaneous absorption of salicylic acid in a 6% salicylic acid gel in four patients with extensive active psoriasis, Taylor and Halprin showed that the peak serum salicylate levels never exceeded 5 mg/100 mL even though more than 60% of the applied salicylic acid was absorbed. Systemic toxic reactions are usually associated with much higher serum levels (30 to 40 mg/100 mL). Peak serum levels occurred within five hours of the topical application under occlusion. The sites were occluded for 10 hours over the entire body surface below the neck. Since salicylates are distributed in the extracellular space, patients with a contracted extracellular space due to dehydration or diuretics have higher salicylate levels than those with a normal extracellular space (See


PRECAUTIONS).


The major metabolites identified in the urine after topical administration are salicyluric acid (52%), salicylate glucuronides (42%) and free salicylic acid (6%). The urinary metabolites after percutaneous absorption differ from those after oral salicylate administration; those derived from percutaneous absorption contain more salicylate glucuronides and less salicyluric and salicylic acid. Almost 95% of a single dose of salicylate is excreted within 24 hours of its entrance into the extracellular space.Fifty to eighty percent of salicylate is protein bound to albumin. Salicylates compete with the binding of several drugs and can modify the action of these drugs; by similar competitive mechanisms other drugs can influence the serum levels of salicylate (See


PRECAUTIONS).

Indications And Usage

For Dermatologic Use: Salex


® is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).


For Podiatric Use: Salex


® is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares.

Contraindications

Salex


® should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. Salex


® should not be used in children under 2 years of age.

Warnings

Prolonged and repeated daily use over large areas, especially in children and those patients with significant renal or hepatic impairment, could result in salicylism. Patients should be advised not to apply occlusive dressings, clothing or other occlusive topical products such as petrolatum-based ointments to prevent excessive systemic exposure to salicylic acid. Excessive application of the product other than is needed to cover the affected area will not result in a more rapid therapeutic benefit. Concomitant use of other drugs which may contribute to elevated serum salicylate levels should be avoided where the potential for toxicity is present. In children under 12 years of age and those patients with renal or hepatic impairment, the area to be treated should be limited and the patient monitored closely for signs of salicylate toxicity: nausea, vomiting, dizziness, loss of hearing, tinnitus, lethargy, hyperpnea, diarrhea, and psychic disturbances. In the event of salicylic acid toxicity, the use of Salex


® should be discontinued. Fluids should be administered to promote urinary excretion. Treatment with sodium bicarbonate (oral or intravenous) should be instituted as appropriate. Patients should be cautioned against the use of oral aspirin and other salicylate containing medications, such as sports injury creams, to avoid additional excessive exposure to salicylic acid. Where needed, aspirin should be replaced by an alternative non-steroidal anti-inflammatory agent that is not salicylate based.


Due to potential risk of developing Reye's syndrome, salicylate products should not be used in children and teenagers with varicella or influenza, unless directed by a physician.

Precautions

For external use only. Avoid contact with eyes and other mucous membranes.

Drug Interactions

The following interactions are from a published review and include reports concerning both oral and topical salicylate administration. The relationship of these interactions to the use of Salex


® is not known.

Laboratory Tests

The following alterations of laboratory tests have been reported during salicylate therapy:LABORATORY TESTSEFFECT OF SALICYLATESThyroid FunctionDecreased PBI; increased T


3 uptake.


Urinary SugarFalse negative with glucose oxidase; false positive with Clinitest with high-dose salicylate therapy (2-5g q.d.).5-Hydroxyindole acetic acidFalse negative with fluorometric test.Acetone, ketone bodiesFalse positive FeCl


3 in Gerhardt reaction; red color persists with boiling.


17-OH corticosteroidsFalse reduced values with >4.8g q.d. salicylate.Vanilmandelic acid False reduced values.Uric acidMay increase or decrease depending on dose.ProthrombinDecreased levels; slightly increased prothrombin time.

Teratogenic Effects

Salicylic acid has been shown to be teratogenic in rats and monkeys. It is difficult to extrapolate from oral doses of acetylsalicylic acid used in these studies to topical administration as the oral dose to monkeys may represent six times the maximal daily human dose of salicylic acid when applied topically over a large body surface. There are no adequate and well-controlled studies in pregnant women. Salex


® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Because of the potential for serious adverse reactions in nursing infants from the mother's use of Salex


®, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If used by nursing mothers, it should not be used on the chest area to avoid the accidental contamination of the child.

Carcinogenesis, Mutagenesis, Impairment Of Fertility

No data are available concerning potential carcinogenic or reproductive effects of Salex


®. Salicylic acid has been shown to lack mutagenic potential in the Ames


Salmonella test.

Adverse Reactions

Excessive erythema and scaling conceivably could result from use on open skin lesions.

Overdosage

See


Warnings.

Dosage And Administration

The preferable method of use is to apply Salex


® thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for at least five minutes prior to application. The medication is washed off in the morning and if excessive drying and/or irritation is observed, a bland cream or lotion may be applied. Once clearing is apparent, the occasional use of Salex


® will usually maintain the remission. In those areas where occlusion is difficult or impossible, application may be made more frequently; hydration by wet packs or baths prior to application apparently enhances the effect (See


WARNINGS). Unless hands are being treated, hands should be rinsed thoroughly after application. Excessive repeated application of Salex


® will not necessarily increase its therapeutic benefit, but could result in increased local intolerance and systemic adverse effects such as salicylism.

How Supplied

Salex
® Cream is available in a 454 g (16 oz.) jar -
NDC 0295-1040-36
Salex
® Lotion is available in a 8 fl. oz. (237 mL) bottle -
NDC 0295-1039-28

Storage And Handling

Store at controlled room temperature 20° to 25°C (68° to 77°F). Do not freeze.

References

(1) Data on file.

* Please review the disclaimer below.

Previous Code
0295-1039
Next Code
0295-1042